NEW YORK (GenomeWeb News) – Caprion Proteomics said today that it has acquired the biomarker services division of PPD, a contract research firm focused on pharmaceutical services based in Wilmington, NC, for an undisclosed sum.

Montreal-based Caprion said that it closed the acquisition of PPD Biomarker Discovery Services on December 31, 2009.

Caprion said that it will fulfill PPD’s existing contractual biomarker obligations from its Montreal facilities and from a new US facility to be called Caprion Proteomics, US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.